tiprankstipranks
Veracyte reports Q4 EPS (5c), consensus (15c)
The Fly

Veracyte reports Q4 EPS (5c), consensus (15c)

Reports Q4 revenue $80.297M, consensus $74.91M. "We had an outstanding fourth quarter, driving record revenue and operating cash flows, achieving the best quarter ever for both our Decipher prostate and Afirma thyroid tests," said Marc Stapley, Veracyte’s chief executive officer. "Moreover, throughout 2022, we invested in our long-term growth drivers to deliver on our promise of empowering clinicians with high-value insights to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Moving into 2023, we have a clear strategy, strong financial position, and significant momentum to advance our vision of transforming cancer care for patients all over the world."

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on VCYT:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles